Unisphere Establishment’s Moderna MRNA Stock Holding History

Unisphere Establishment’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-600,000	Closed	-$59.7M	–	71
2023 Q4	$59.7M	Buy	+600,000	New	+$50.5M	0.62%	27

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Unisphere Establishment's MRNA Position: Q1 2024 in Review

Unisphere Establishment sold out of Moderna (MRNA) in Q1 2024, closing a stake of 600,000 shares — an estimated $59.7M sold.

Unisphere Establishment first reported a position in MRNA in Q4 2023 and held it in 1 quarter. The position peaked at $59.7M in Q4 2023. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

Unisphere Establishment reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
Unisphere Establishment sold 600,000 Moderna shares in Q1 2024, an estimated $59.7M.
Unisphere Establishment first reported a position in Moderna in Q4 2023 and held it in 1 quarter.
Unisphere Establishment's Moderna position peaked at $59.7M in Q4 2023.
902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Unisphere Establishment's 13F filing for Q1 2024, filed 13 May 2024.